RCS - Spexis AG - Annual General Meeting
27/04/2022 09:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220427:nRSa5097Ja&default-theme=true
RNS Number : 5097J Spexis AG 27 April 2022
Spexis AG / Key word(s): AGMEGM
Spexis Annual General Meeting 2022
27-Apr-2022
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 27, 2022
Spexis Annual General Meeting 2022
Spexis AG (SIX: SPEX) today announced that its shareholders approved all
proposals of the Board of Directors at the 25(th) Annual General Meeting (AGM)
with a significant majority. In line with the COVID-19 Ordinance 3 of the
Swiss Federal Council, shareholders were not allowed to attend the AGM in
person. The independent proxy represented 25.6% percent of the company's
shares.
The members of the Board of Directors, Jeffrey Wager, Kuno Sommer, Bernard
Bollag, Daniel Hartmann, Robert Clarke, and Dennis Ausiello, were re-elected
for a further year in office. In addition, shareholders confirmed Jeffrey
Wager as Chairman of the Board of Directors. The agenda items on compensation
for the members of the Board of Directors and the executive management were
also approved. Furthermore, the increases to the Company's authorized and
conditional share capital were approved. The management report, the
consolidated financial statements, and the annual financial statements for
2021 were also approved.
"On behalf of the Board of Directors, I would like to thank all of Spexis'
shareholders for their trust and support at today's AGM," said Jeffrey Wager,
Chairman of the Board of Directors.
For further information please contact:
For Investors: For Media:
Hernan Levett
Dr. Stephan Feldhaus
Chief Financial Officer
Feldhaus & Partner
Spexis AG.
+41 79 865 92 56
+41 61 567 16 00 feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
IR@spexisbio.com (mailto:IR@spexisbio.com)
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis AGM results
(https://eqs-cockpit.com/c/fncls.ssp?u=633bb4607588d6f986c253230bcd52de)
End of ad hoc announcement
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis AGM results
(https://eqs-cockpit.com/c/fncls.ssp?u=633bb4607588d6f986c253230bcd52de)
End of ad hoc announcement
Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@spexisbio.com
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1336109
End of Announcement EQS News Service
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUBSNRUBUSURR